罕见遗传性肥胖症的新型治疗方法：叙述性综述。

Novel therapeutics in rare genetic obesities: A narrative review.

机构信息

Assistance Publique Hôpitaux de Paris, Trousseau Hospital, Pediatric Nutrition and Gastroenterology Department, French Reference Center for Prader-Willi Syndrome and other rare obesities (PRADORT), Paris, France; Systemic approaches, NutriOmics research group, 75013 Paris, France; Sorbonne Université, INSERM, Nutrition and obesities, NutriOmics research group, 75013 Paris, France.

出版信息

Pharmacol Res. 2023 May;191:106763. doi: 10.1016/j.phrs.2023.106763. Epub 2023 Apr 8.

DOI:10.1016/j.phrs.2023.106763

PMID:37037398

Abstract

The better understanding of the molecular causes of rare genetic obesities and its associated phenotype involving the hypothalamus allows today to consider innovative therapeutics focused on hunger control. Several new pharmacological molecules benefit patients with monogenic or syndromic obesity. They are likely to be among the treatment options for these patients in the coming years, helping clinicians and patients prevent rapid weight progression and eventually limit bariatric surgery procedures, which is less effective in these patients. Their positioning in the management of such patients will be needed to be well defined to develop precision medicine in genetic forms of obesity.

摘要

对罕见遗传性肥胖及其涉及下丘脑的相关表型的分子病因的更好理解，使得今天能够考虑针对饥饿控制的创新性治疗方法。几种新的药理分子使患有单基因或综合征性肥胖的患者受益。它们可能是未来几年这些患者的治疗选择之一，有助于临床医生和患者预防体重快速增长，并最终限制减肥手术，因为减肥手术对这些患者的效果较差。为了在遗传性肥胖形式中发展精准医学，需要明确这些药物在这些患者管理中的定位。